Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics reports developments as a commercial-stage biopharmaceutical company focused on therapies for rare diseases. Recurring updates center on MIPLYFFA (arimoclomol), its U.S.-approved treatment for Niemann-Pick disease type C, including commercialization, patient access, regulatory activity and diagnostic-support initiatives tied to NPC.
Zevra news also covers financial results, pipeline programs in rare diseases such as vascular Ehlers-Danlos syndrome, and corporate actions that shape its portfolio. Recent company updates include the completed sale of the serdexmethylphenidate, or SDX, portfolio, including AZSTARYS and KP1077, as well as governance and executive-compensation announcements under Nasdaq rules.
Zevra Therapeutics (NasdaqGS: ZVRA) submitted U.S. Patent No. 11,707,456 for MIPLYFFA (arimoclomol) to the FDA for Orange Book listing. The patent expires November 19, 2041, aiming to strengthen exclusivity for treating Niemann-Pick disease type C.
A separate patent term extension request for U.S. Patent No. 11,045,460, currently expiring in 2029, remains pending with the U.S. Patent and Trademark Office.
Zevra Therapeutics (NasdaqGS: ZVRA) granted stock options to four new employees under its 2023 Employment Inducement Award Plan, consistent with Nasdaq Rule 5635(c)(4).
The options cover an aggregate of 33,000 shares, vesting over four years with 25% after one year and the balance in three equal annual installments.
Zevra Therapeutics (NasdaqGS: ZVRA) will present at the H.C. Wainwright BioConnect Investor Conference in New York on May 19, 2026, at 9:00 a.m. ET.
Executive leadership will present and hold one-on-one meetings, with a live webcast available via the Investor Relations section of Zevra’s website.
Zevra (NasdaqGS: ZVRA) reported Q1 2026 results on May 6, 2026. Net revenue was $36.2 million, up 78% year-over-year, including $24.6 million from MIPLYFFA. The company completed a $50.0 million sale of its SDX portfolio and prepaid a $63.1 million term loan, leaving cash of $236.8 million.
Pipeline updates include Phase 3 DiSCOVER enrollment progress (62 patients, two events) and an EMA review of arimoclomol for NPC; a conference call was held May 6, 2026.
Zevra Therapeutics (NasdaqGS: ZVRA) will report first-quarter 2026 corporate and financial results on Wednesday, May 6, 2026 via a news release after the market close and host a conference call/audio webcast at 4:30 p.m. ET.
A link and replay (available for 90 days beginning ~5:30 p.m. ET) will be on the Events & Presentations page at investors.zevra.com. Telephone dial-in and Conference ID ZVRAQ126 are provided for participants.
Zevra Therapeutics (Nasdaq: ZVRA) granted an inducement equity award to new CFO Justin Renz effective March 18, 2026 under its 2023 Employment Inducement Award Plan.
The company approved a new-hire option for 300,000 shares with a 10-year term, exercise price of $9.55 (closing price on March 18, 2026), and four-year vesting subject to continued service. The award was approved under Nasdaq Rule 5635(c)(4).
Zevra Therapeutics (NasdaqGS: ZVRA) agreed to sell its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million on April 4, 2026.
As part of the transaction the parties mutually settled prior Delaware litigation, and Zevra repaid the principal on its $63 million term loan, leaving a debt-free balance sheet.
GeneDx (Nasdaq: WGS) and Zevra Therapeutics announced a Sponsored Genetic Testing Program to expand access to GeneDx’s ExomeDx test for U.S. patients with suspected Niemann-Pick disease type C (NPC). Eligible patients may receive testing at no charge, with results available in as little as three weeks.
De-identified data from the program will be added to GeneDx Infinity™, aiming to improve NPC diagnosis speed and support clinical decision-making as new therapies emerge. Zevra will provide financial support for the program.
Zevra (NASDAQ: ZVRA) reported Q4 revenue of $34.1M (Q4 growth 31% QoQ) and FY2025 net revenue of $106.5M, driven by MIPLYFFA net revenue $87.4M. FY2025 net income was $83.2M ($1.40 basic, $1.35 diluted). Cash and securities totaled $238.9M at year-end.
Regulatory progress: EMA MAA under review; U.S. EAP enrolled 113 patients; Phase 3 DiSCOVER enrollment ongoing (52 patients).
Zevra Therapeutics (Nasdaq: ZVRA) appointed Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz brings more than 25 years of biopharmaceutical financial leadership, experience in capital markets and commercial launches, and holds CPA credentials and multiple advanced degrees.
This leadership change positions Zevra to strengthen its financial foundation as it advances commercialization and execution of its rare disease strategy.